S&P 500   4,289.33 (-0.24%)
DOW   33,519.45 (-0.44%)
QQQ   357.89 (-0.03%)
AAPL   171.13 (+0.26%)
MSFT   315.92 (+0.73%)
META   301.96 (-0.66%)
GOOGL   130.95 (-1.03%)
AMZN   126.82 (+0.67%)
TSLA   249.00 (+1.06%)
NVDA   435.13 (+0.98%)
NIO   8.95 (+0.45%)
BABA   86.88 (+1.57%)
AMD   103.28 (+0.51%)
T   14.96 (-0.33%)
F   12.42 (-1.11%)
MU   67.76 (+3.93%)
CGC   0.79 (-2.65%)
GE   110.15 (-1.95%)
DIS   80.61 (+0.60%)
AMC   8.02 (+2.95%)
PFE   33.09 (+3.12%)
PYPL   58.24 (+0.10%)
NFLX   376.86 (+0.13%)
S&P 500   4,289.33 (-0.24%)
DOW   33,519.45 (-0.44%)
QQQ   357.89 (-0.03%)
AAPL   171.13 (+0.26%)
MSFT   315.92 (+0.73%)
META   301.96 (-0.66%)
GOOGL   130.95 (-1.03%)
AMZN   126.82 (+0.67%)
TSLA   249.00 (+1.06%)
NVDA   435.13 (+0.98%)
NIO   8.95 (+0.45%)
BABA   86.88 (+1.57%)
AMD   103.28 (+0.51%)
T   14.96 (-0.33%)
F   12.42 (-1.11%)
MU   67.76 (+3.93%)
CGC   0.79 (-2.65%)
GE   110.15 (-1.95%)
DIS   80.61 (+0.60%)
AMC   8.02 (+2.95%)
PFE   33.09 (+3.12%)
PYPL   58.24 (+0.10%)
NFLX   376.86 (+0.13%)
S&P 500   4,289.33 (-0.24%)
DOW   33,519.45 (-0.44%)
QQQ   357.89 (-0.03%)
AAPL   171.13 (+0.26%)
MSFT   315.92 (+0.73%)
META   301.96 (-0.66%)
GOOGL   130.95 (-1.03%)
AMZN   126.82 (+0.67%)
TSLA   249.00 (+1.06%)
NVDA   435.13 (+0.98%)
NIO   8.95 (+0.45%)
BABA   86.88 (+1.57%)
AMD   103.28 (+0.51%)
T   14.96 (-0.33%)
F   12.42 (-1.11%)
MU   67.76 (+3.93%)
CGC   0.79 (-2.65%)
GE   110.15 (-1.95%)
DIS   80.61 (+0.60%)
AMC   8.02 (+2.95%)
PFE   33.09 (+3.12%)
PYPL   58.24 (+0.10%)
NFLX   376.86 (+0.13%)
S&P 500   4,289.33 (-0.24%)
DOW   33,519.45 (-0.44%)
QQQ   357.89 (-0.03%)
AAPL   171.13 (+0.26%)
MSFT   315.92 (+0.73%)
META   301.96 (-0.66%)
GOOGL   130.95 (-1.03%)
AMZN   126.82 (+0.67%)
TSLA   249.00 (+1.06%)
NVDA   435.13 (+0.98%)
NIO   8.95 (+0.45%)
BABA   86.88 (+1.57%)
AMD   103.28 (+0.51%)
T   14.96 (-0.33%)
F   12.42 (-1.11%)
MU   67.76 (+3.93%)
CGC   0.79 (-2.65%)
GE   110.15 (-1.95%)
DIS   80.61 (+0.60%)
AMC   8.02 (+2.95%)
PFE   33.09 (+3.12%)
PYPL   58.24 (+0.10%)
NFLX   376.86 (+0.13%)
NASDAQ:MYGN

Myriad Genetics (MYGN) Stock Forecast, Price & News

$16.12
-0.67 (-3.99%)
(As of 01:28 PM ET)
Compare
Today's Range
$15.66
$17.14
50-Day Range
$15.99
$23.08
52-Week Range
$13.92
$24.21
Volume
521,973 shs
Average Volume
563,689 shs
Market Capitalization
$1.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.20

Myriad Genetics MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
49.6% Upside
$24.20 Price Target
Short Interest
Bearish
5.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
0.17mentions of Myriad Genetics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.61) to ($0.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

666th out of 972 stocks

Diagnostic Substances Industry

9th out of 13 stocks


MYGN stock logo

About Myriad Genetics (NASDAQ:MYGN) Stock

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. Further, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

MYGN Price History

MYGN Stock News Headlines

This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
See More Headlines
Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

MYGN Company Calendar

Last Earnings
8/03/2023
Today
9/29/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MYGN
CUSIP
62855J10
Employees
2,600
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$24.20
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+44.1%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-112,000,000.00
Pretax Margin
-37.92%

Debt

Sales & Book Value

Annual Sales
$678.40 million
Cash Flow
$0.20 per share
Book Value
$10.93 per share

Miscellaneous

Free Float
80,245,000
Market Cap
$1.37 billion
Optionable
Optionable
Beta
1.78

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Paul J. Diaz (Age 61)
    CEO, Pres & Director
    Comp: $1.88M
  • Mr. R. Bryan Riggsbee (Age 52)
    Exec. VP, CFO & Treasurer
    Comp: $845.15k
  • Ms. Nicole LambertMs. Nicole Lambert (Age 49)
    Chief Operating Officer
    Comp: $746.91k
  • Dr. Kevin Richard Haas Ph.D. (Age 37)
    Chief Technology Officer
    Comp: $580.36k
  • Mr. Mark S. Verratti (Age 55)
    Chief Commercial Officer
    Comp: $794.85k
  • Ms. Natalie Munk (Age 42)
    Principal Accounting Officer
  • Dr. Dale Muzzey Ph.D. (Age 43)
    Chief Scientific Officer
  • Mr. Matthew Scalo
    Sr. VP of Investor Relations
  • Dr. Clivetty Martinez
    Chief Compliance Officer
  • Ms. Pamela Wong (Age 55)
    Chief Legal Officer













MYGN Stock - Frequently Asked Questions

Should I buy or sell Myriad Genetics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View MYGN analyst ratings
or view top-rated stocks.

What is Myriad Genetics' stock price forecast for 2023?

5 brokers have issued 1 year target prices for Myriad Genetics' shares. Their MYGN share price forecasts range from $17.00 to $28.00. On average, they predict the company's stock price to reach $24.20 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price.
View analysts price targets for MYGN
or view top-rated stocks among Wall Street analysts.

How have MYGN shares performed in 2023?

Myriad Genetics' stock was trading at $14.51 on January 1st, 2023. Since then, MYGN stock has increased by 15.7% and is now trading at $16.79.
View the best growth stocks for 2023 here
.

When is Myriad Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our MYGN earnings forecast
.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) released its earnings results on Thursday, August, 3rd. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $183.50 million for the quarter, compared to analyst estimates of $187.16 million. Myriad Genetics had a negative net margin of 35.51% and a negative trailing twelve-month return on equity of 9.43%. The business's revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.06) EPS.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of -$0.36--$0.24 for the period, compared to the consensus EPS estimate of -$0.32. The company issued revenue guidance of $730.00 million-$750.00 million, compared to the consensus revenue estimate of $742.12 million.

What is Paul Diaz's approval rating as Myriad Genetics' CEO?

12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

How do I buy shares of Myriad Genetics?

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $16.79.

How much money does Myriad Genetics make?

Myriad Genetics (NASDAQ:MYGN) has a market capitalization of $1.37 billion and generates $678.40 million in revenue each year. The company earns $-112,000,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

How many employees does Myriad Genetics have?

The company employs 2,600 workers across the globe.

Does Myriad Genetics have any subsidiaries?
The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.
Read More
How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The official website for the company is www.myriad.com. The company can be reached via phone at (801) 584-3600, via email at sgleason@myriad.com, or via fax at 801-584-3640.

This page (NASDAQ:MYGN) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -